Historically, people with bleeding disorders who received replacement therapy have long faced a higher risk of developing viral hepatitis and cirrhosis. However, new treatments have significantly lowered this risk. Despite these advancements, liver health still depends on several factors, and these factors may still lead to complications such as liver cancer and liver failure. “The management of liver disease in people with congenital bleeding disorders: guidance from EAHAD, EHC, ISTH, WFH”—published on September 11, 2024 in the Journal of Thrombosis and Haemostasis (JTH)—aims to offer guidance to PWBDs on ways to protect liver health and manage complications. To read the full article, please click here.